![Capricor Therapeutics Inc](/common/images/company/N_CAPR.png)
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.32 | -6.8085106383 | 4.7 | 4.93 | 4.32 | 212885 | 4.61772034 | CS |
4 | -0.34 | -7.20338983051 | 4.72 | 5.26 | 4.23 | 567377 | 4.71829962 | CS |
12 | -0.9 | -17.0454545455 | 5.28 | 6.5336 | 4.23 | 426060 | 5.12668844 | CS |
26 | 0.23 | 5.5421686747 | 4.15 | 7.28 | 3.56 | 362647 | 5.31508048 | CS |
52 | -0.07 | -1.57303370787 | 4.45 | 8.2212 | 2.68 | 303556 | 4.88576046 | CS |
156 | -0.42 | -8.75 | 4.8 | 8.2212 | 2.56 | 255335 | 4.62998238 | CS |
260 | -0.57 | -11.5151515152 | 4.95 | 12.32 | 0.88 | 740079 | 5.90171233 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.